Schwab Charles Investment Management Inc. increased its holdings in NxStage Medical, Inc. (NASDAQ:NXTM) by 8.8% in the second quarter, HoldingsChannel.com reports. The fund owned 350,949 shares of the medical device company’s stock after acquiring an additional 28,433 shares during the period. Schwab Charles Investment Management Inc.’s holdings in NxStage Medical were worth $9,792,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the stock. SG Americas Securities LLC lifted its holdings in NxStage Medical by 154.6% in the first quarter. SG Americas Securities LLC now owns 26,576 shares of the medical device company’s stock worth $661,000 after acquiring an additional 16,136 shares during the last quarter. Swiss National Bank lifted its holdings in NxStage Medical by 11.2% in the first quarter. Swiss National Bank now owns 136,400 shares of the medical device company’s stock worth $3,391,000 after acquiring an additional 13,700 shares during the last quarter. Aperio Group LLC lifted its holdings in NxStage Medical by 26.5% in the first quarter. Aperio Group LLC now owns 13,847 shares of the medical device company’s stock worth $344,000 after acquiring an additional 2,899 shares during the last quarter. BlackRock Inc. lifted its holdings in NxStage Medical by 8.9% in the first quarter. BlackRock Inc. now owns 4,787,684 shares of the medical device company’s stock worth $119,023,000 after acquiring an additional 390,594 shares during the last quarter. Finally, Gabelli Funds LLC lifted its holdings in NxStage Medical by 8.7% in the first quarter. Gabelli Funds LLC now owns 242,724 shares of the medical device company’s stock worth $6,034,000 after acquiring an additional 19,400 shares during the last quarter. 83.12% of the stock is owned by institutional investors.

Shares of NASDAQ NXTM opened at $28.17 on Monday. NxStage Medical, Inc. has a 52-week low of $22.70 and a 52-week high of $28.75. The stock has a market capitalization of $1.85 billion, a price-to-earnings ratio of -128.05 and a beta of -0.04.

A number of equities analysts have issued reports on the stock. BidaskClub cut shares of NxStage Medical from a “hold” rating to a “sell” rating in a report on Monday, September 17th. Zacks Investment Research cut shares of NxStage Medical from a “hold” rating to a “sell” rating in a report on Saturday, August 11th. Finally, ValuEngine cut shares of NxStage Medical from a “buy” rating to a “hold” rating in a report on Tuesday, August 7th. Two analysts have rated the stock with a sell rating and three have assigned a hold rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $30.00.

NxStage Medical Company Profile

NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.

Read More: Dividend Stocks – Are They Right For You?

Want to see what other hedge funds are holding NXTM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NxStage Medical, Inc. (NASDAQ:NXTM).

Institutional Ownership by Quarter for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.